atmF Report on Global Access to Antibiotics
The ATMF report addresses global antibiotic access, highlighting pharmaceutical industry challenges, particularly in developing drugs for superbugs. It explains AMR, predicting 10 million annual deaths by 2050. The report evaluates five key drug projects from companies like GSK and Pfizer, noting innovation and accessibility issues. It criticizes the lack of LMIC registration plans and affordability strategies. Encouragingly, it notes pediatric trials and praises partnerships aiding smaller businesses.
